Indivior (NasdaqGS:INDV) 2025 Conference November 13, 2025 08:40 AM ET Company ParticipantsRyan Preblick - CFOJoe Ciaffoni - CEOConference Call ParticipantsChristian Glenney - Healthcare AnalystChristian GlenneyMorning, everybody. Welcome to the Stifel Healthcare Conference once more. I'm Christian Glenney, Healthcare Analyst based out of our London Office. Delighted to be joined in the session by Joe Ciaffoni, CEO, Ryan Preblick, CFO of Indivior, a $4 billion Market cap company, Annual Turnover about $1.2 ...

Core Insights - Ensysce Biosciences, Inc. (ENSC) stock experienced a nearly 100% increase in value, with significant trading volume surpassing the average of 81.23K shares [1] - The company received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent related to Enzyme-Cleavable Methadone Prodrugs, which includes claims for both composition and methods of use [1] Group 1: Product Development and Clinical Trials - PF9001, the medication associated with the new patent, aims to provide a safer treatment for opioid use disorder (OUD) utilizing Ensysce's TAAP and MPAR technologies for abuse deterrence and overdose protection [2] - Methadone has been traditionally used for OUD, but its application has been limited due to concerns about cardiac side effects and overdose risks [3] - Ensysce has developed PF9001, which shows reduced cardiotoxicity and validates the MPAR technology for overdose protection, with indications of a prolonged effect from once-daily dosing [3] Group 2: Clinical Trial Results - The National Institute on Drug Abuse supported the research for the patent, and Ensysce completed Part 1 of its second clinical trial for PF614-MPAR, which demonstrated effective overdose protection while relieving severe pain [4] - The trial confirmed that a 100 mg dosage of PF614-MPAR provides overdose protection when doses exceed the prescribed amount, showing reduced maximum oxycodone release compared to PF614 alone [5] - Safety data from the trial indicated no unexpected adverse events, and the study will continue to evaluate food effects and repeat dosing [6] Group 3: Financial Activities - Ensysce Biosciences announced a registered direct offering of approximately $1.1 million in March, issuing 315,188 shares at a price of $3.49 per share [7] - Following the news, ENSC stock rose by 96.30%, reaching a price of $3.67 [7]